Drug maker Krka's group net profit down 28% in Jan-Jun

Novo Mesto, 6 July - The group around drug company Krka reported an estimated net profit of EUR 170 million for the first half of 2023, a 28% year-on-year decrease that the company attributed to high foreign exchange gains in 2022. Revenue grew by 7% to EUR 920 million and operating profit (EBIT) by 9% to a six-month company record of EUR 236 million.